醫院內感染市場規模、佔有率和成長分析（按類型、治療方法、感染類型、最終用戶和地區）- 產業預測 2025-2032

2023 年全球醫院內感染市場規模價值 304 億美元，預計將從 2024 年的 308.6 億美元成長到 2032 年的 347.6 億美元，預測期內（2025-2032 年）的複合年成長率為 1.5%。

由於人們對醫院內感染（HAI）認知的不斷提高、預防交叉感染的迫切需求以及醫療機構中感染疾病爆發的不斷增加，感染控制市場正在經歷強勁成長。滅菌設備、清洗和消毒劑、防護屏障和內視鏡再處理工具等關鍵產品在最大限度地減少醫院內感染方面發揮關鍵作用。此外，政府倡導改善感染控制措施的支持措施進一步加強了該產業的發展。醫院、地方和國家層級採用全面的感染預防指南以及提高監測技術的整合度是推動市場擴張的關鍵因素。隨著認知和依從性的提高，對有效感染控制產品和服務的需求只增不減，這使得這成為一個充滿活力且重要的市場。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

醫院感染市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 裝置
  • 滅菌設備
  • 消毒設備
• 耗材
  • 消毒劑
  • 滅菌耗材
  • 其他
• 服務

醫院感染市場規模（依治療方法及複合年成長率） (2025-2032)

• 市場概況
• 抗菌
• 抗病毒藥物
• 抗真菌
• 其他

醫院感染市場規模（按感染類型和複合年成長率） (2025-2032)

• 市場概況
• 血流感染疾病
• 人工呼吸器相關性肺炎 (VAP)
• 尿道感染
• 手術部位感染
• 胃腸道感染疾病
• 其他

醫院感染市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院和診所
• 門診手術中心
• 其他

醫院感染市場規模（依地區分類）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• STERIS plc（Ireland）
• Getinge AB（Sweden）
• 3M（USA）
• Ecolab Inc.（USA）
• Diversey Holdings, Ltd.（USA）
• Roche Holding AG（Switzerland）
• Abbott Laboratories（USA）
• bioMerieux SA（France）
• Thermo Fisher Scientific Inc.（USA）
• Becton, Dickinson and Company（BD）（USA）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Sanofi SA（France）
• Medtronic plc（Ireland）
• Cardinal Health（USA）
• Johnson & Johnson（USA）

結論和建議

Global Hospital-Acquired Infections Market size was valued at USD 30.4 billion in 2023 and is poised to grow from USD 30.86 billion in 2024 to USD 34.76 billion by 2032, growing at a CAGR of 1.5% during the forecast period (2025-2032).

The infection control market is witnessing robust growth driven by heightened awareness of Hospital Acquired Infections (HAIs), the urgent need to combat cross infections, and the rising prevalence of infectious diseases within healthcare facilities. Key products such as sterilization equipment, cleaning and disinfection agents, protective barriers, and endoscope reprocessing tools play crucial roles in minimizing hospital-acquired infections. Additionally, supportive government initiatives advocating for improved infection control measures further bolster this sector. The adoption of comprehensive infection prevention guidelines at hospital, regional, and national levels, along with the growing integration of monitoring technologies, are significant factors fueling market expansion. As awareness and compliance grow, the demand for effective infection control products and services continues to rise, making this a dynamic and vital market space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hospital-Acquired Infections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hospital-Acquired Infections Market Segmental Analysis

Global Hospital-Acquired Infections Market is segmented by Type, Treatment, Infection Type, End User and region. Based on Type, the market is segmented into Equipment, Consumables and Services. Based on Treatment, the market is segmented into Antibacterial, Antiviral, Antifungal and Others. Based on Infection Type, the market is segmented into Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections market is poised for growth driven by the rising number of surgical procedures performed globally. According to the World Health Organization, approximately 235 million major surgeries are carried out annually, a trend fueled by the increasing prevalence of obesity, lifestyle-related diseases, an aging population, and a surge in spine and sports injuries. As more surgeries take place, the demand for surgical tools and medical devices escalates. The recognized advantages of sterilized equipment, coupled with heightened awareness of their importance in healthcare environments, are expected to significantly boost the demand for services addressing hospital-acquired infections.

Restraints in the Global Hospital-Acquired Infections Market

The growth of the Global Hospital-Acquired Infections market is hindered by apprehensions surrounding the safety of reprocessed medical instruments. While reusing devices like surgical forceps, endoscopes, and stethoscopes can significantly reduce costs and environmental waste for healthcare providers, doubts persist regarding the efficacy and cleanliness of these reprocessed items. Improper cleaning and sterilization processes might leave behind blood, tissue, and other biological residue, elevating the risk of surgical-site infections (SSIs) and hospital-acquired infections (HAIs). Furthermore, any residual materials, such as chemical disinfectants, could lead to tissue irritation. This uncertainty is resulting in limited acceptance of device reprocessing among hospital administrators and clinicians.

Market Trends of the Global Hospital-Acquired Infections Market

The Global Hospital-Acquired Infections (HAIs) market is experiencing significant growth, propelled by a surge in chronic diseases like diabetes, cardiovascular disorders, and gastrointestinal conditions. With environmental and lifestyle factors contributing to rising disease prevalence-projected to escalate from 537 million diabetics in 2021 to approximately 783 million by 2045-there will be an uptick in surgical procedures, consequently elevating the risk of HAIs. Increased awareness and need for stringent sterilization and disinfection protocols will further drive demand for infection control devices. As such, the market is poised for robust expansion, addressing both the rise in surgical interventions and the necessity for enhanced infection prevention measures.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hospital-Acquired Infections Market Size by Type & CAGR (2025-2032)

• Market Overview
• Equipment
  • Sterilization Equipment
  • Disinfection Equipment
• Consumables
  • Disinfectants
  • Sterilization Consumables
  • Others
• Services

Global Hospital-Acquired Infections Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Antibacterial
• Antiviral
• Antifungal
• Others

Global Hospital-Acquired Infections Market Size by Infection Type & CAGR (2025-2032)

• Market Overview
• Bloodstream Infections
• Ventilator-Associated Pneumonia (VAP)
• Urinary Tract Infection
• Surgical-Site Infection
• Gastrointestinal Infections
• Others

Global Hospital-Acquired Infections Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Hospital-Acquired Infections Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Infection Type, End User)
  • US
  • Canada
• Europe (Type, Treatment, Infection Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Infection Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Infection Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Infection Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• STERIS plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ecolab Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diversey Holdings, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations